Aim Immunotech Stock News

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET

PharmaCyte Biotech (OTCMKTS:PMCBD) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Earnings and Valuation This table compares PharmaCyte Biotech and AIM ImmunoTechs gross revenue, earnings per [] The post Critical Review: PharmaCyte Biotech (OTCMKTS:PMCBD) & AIM ImmunoTech (NYSE:AIM) appeared first on ETF Daily News .

Arkadios Wealth Advisors purchased a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 21,597 shares of the companys stock, valued at approximately $43,000. Other hedge funds have also recently added []

OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of

AIM ImmunoTech Inc (NYSE:AIM) has announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzb

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming inve

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.

AIM ImmunoTech (NYSE: AIM) is one of 237 public companies in the Biological products, except diagnostic industry, but how does it contrast to its peers? We will compare AIM ImmunoTech to related companies based on the strength of its dividends, analyst recommendations, risk, valuation, profitability, earnings and institutional ownership. Profitability This table compares AIM ImmunoTech [] The post Critical Contrast: AIM ImmunoTech (AIM) & Its Competitors appeared first on ETF Daily News .

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming invest

During the last session, AIM ImmunoTech Inc. (AMEX:AIM)s traded shares were 0.48 million, with the beta value of the company hitting -0.90. At the end of the trading day, the stocks price was $1.38, reflecting an intraday gain of 6.98% or $0.09. The 52-week high for the AIM share is $3.06, that puts it down Boom Or Bust: Where Does AIM ImmunoTech Inc. (AMEX: AIM) Stock Go From Here? Read More »

AIM ImmunoTech (NYSE: AIM) is one of 236 public companies in the Biological products, except diagnostic industry, but how does it weigh in compared to its rivals? We will compare AIM ImmunoTech to related companies based on the strength of its earnings, analyst recommendations, profitability, valuation, dividends, risk and institutional ownership. Insider & Institutional Ownership []

Vanguard Group Inc. grew its holdings in shares of AIM ImmunoTech Inc. (NYSE:AIM) by 3.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,993,156 shares of the companys stock after acquiring an additional 66,757 shares during the quarter. Vanguard Group Inc. owned 4.17% of []

AIM ImmunoTech (NYSE:AIM) announced its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters consensus estimate of ($0.08), Fidelity Earnings reports. AIM ImmunoTech had a negative net margin of 13,662.70% and a negative return on equity of 26.80%. AIM opened at $1.59 on Thursday. AIM []

AIM ImmunoTech (NYSE:AIM) issued its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, hitting analysts consensus estimates of ($0.08), Fidelity Earnings reports. AIM ImmunoTech had a negative return on equity of 26.09% and a negative net margin of 12,941.86%. AIM traded down $0.01 during trading on Wednesday, reaching $1.63. 10 []